login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Preliminary results of CT angiography method for assessing haemodynamic significance of coronary lesions released


Wednesday, 11 Jul 2012 12:05
COR Analyzer
COR Analyzer


On 10 July, Rcadia Medical Imaging announced results of an initial study intended to demonstrate the feasibility of a proprietary technique that uses coronary CT angiography studies (cCTA) as a non-invasive alternative to assess the haemodynamic significance of coronary lesions.


“Determining the effect of an intermediate lesion on coronary blood flow is critical to making a treatment decision,” said Shai Levanon, president and CEO, Rcadia. “Currently, the standard technique for evaluating the haemodynamic significance of coronary lesions is by measuring fractional flow reserve (FFR) through invasive coronary catheterisation. Our initial study shows a good correlation to FFR, highlighting the potential of our technology to enhance the diagnostic utility of cCTA and reduce the number of invasive, costly diagnostic cardiac catheterisation produces.”

Levanon noted that Rcadia’s approach builds on its FDA cleared COR Analyzer System, which performs fully automatic detection of coronary stenosis from cCTA studies. “A capability for assessing haemodynamic significance has potential to provide a powerful complement to the COR Analyzer’s ability to identify significant stenosis in suspected patients with coronary artery disease.”


To assess the diagnostic performance of the method, Rcadia conducted a retrospective study based on 44 patients who underwent both cCTA and diagnostic coronary catheterisation with FFR measurements. Assessments using Rcadia’s proprietary technique were performed for 49 of 51 lesions with FFR measurements present in those studies. Two lesions were not evaluated due to poor image quality.


The Rcadia method correctly identified all 11 haemodynamically significant lesions (FFR <=0.8) and 33 of 38 haemodynamically insignificant lesions (FFR>0.8), yielding the sensitivity of 100% and specificity of 87%.




Add New Comment

Related Items


Most popular


Bioresorbable scaffolds have the potential “to be workhorse stents”
Thursday, 07 May 2015
Last year, the GHOST-EU registry indicated that the rate of scaffold thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott Vascular) was “not negilible”. However, as technological ... Bioresorbable scaffolds have the potential “to be workhorse stents”

Merit Medical Systems launches the Prelude Snap splittable sheath introducer
Wednesday, 03 Jun 2015
Merit Medical Systems has launched the Prelude Snap splittable sheath introducer, the design of which is based directly on physician feedback. Merit Medical Systems launches the Prelude Snap splittable sheath introducer

LowerMyDose website launches
Wednesday, 03 Jun 2015
LowerMyDose.com promotes peer-to-peer engagement through real-life experience sharing about the concerns of excessive and unnecessary radiation exposure. LowerMyDose website launches

Features


The importance of the PLATINUM DIVERSITY trial
Wednesday, 24 Jun 2015
The PLATINUM DIVERSITY trial was initiated last year with the aim of evaluating the clinical outcomes of an everolimus-eluting stent (Promus Premier, Boston Scientific) in patient populations that ... The importance of the PLATINUM DIVERSITY trial

The current status of transcatheter pulmonary valve replacement
Tuesday, 09 Jun 2015
The Melody transcatheter pulmonary valve (Medtronic), which received the CE mark in 2006 and FDA humanitarian device exemption approval in 2010, was recently granted FDA premarket approval. In this ... The current status of transcatheter pulmonary valve replacement

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions